Study: Vitamin E protects patients in a randomized study from cisplatin-induced neuropathy

Veröffentlicht:

Von:

The following study deals with the examination of the possible neuroprotective effect of vitamin E in cisplatin-induced neuropathy. It is a randomized, double-blind intervention study in which 108 patients were originally randomized, 41 of which were treated with a cisplatin dose of more than 300 mg/m2. The subjects received either 596 IE D-Alpha-tocopherol (vitamin E) or a placebo every day, starting 1 to 8 days before the start of cisplatin therapy and for 3 months after the end of the therapy. The target parameter was the development of peripheral neuropathy and the severity of the neurological damage was measured with the total neuropathiescore (TNS). The results showed ...
(Symbolbild/natur.wiki)

The following study deals with the examination of the possible neuroprotective effect of vitamin E in cisplatin-induced neuropathy. It is a randomized, double-blind intervention study in which 108 patients were originally randomized, 41 of which were treated with a cisplatin dose of more than 300 mg/m2. The subjects received either 596 IE D-Alpha-tocopherol (vitamin E) or a placebo every day, starting 1 to 8 days before the start of cisplatin therapy and for 3 months after the end of the therapy. The target parameter was the development of peripheral neuropathy and the severity of the neurological damage was measured with the total neuropathiescore (TNS). The results showed that the vitamin E group had significantly lower rates of neurotoxicity (6% vs. 42%) and lower severity of the neurological damage (1.4 TNS vs. 4.1). These results suggest that vitamin E can offer protection against cisplatin-induced neuropathies and patients who are administered cisplatin should be treated with vitamin E preparations several days before the start of chemotherapy.

Details of the study:

Reference

pace A, Giannarelli D, Galie e, et al. Vitamin E-neuroprotection in cisplatin neuropathy. neurology. 2010; 74: 762-766.

Design

randomized, double -blind intervention study

participant

of the 108 patients originally randomized into the study were treated 41 with more than 300 mg/m2 cisplatin. Of these 41 subjects, 17 vitamins E and 24 received a placebo.

study medication and dosage

596 IE D-Alpha-tocopherol or placebo daily, started 1 to 8 days before the start of cisplatin therapy and continued for 3 months after stopping the cisplatin therapy

target parameter

Development of peripheral neuropathy as a result of cisplatin therapy and measurement of the severity of neurological damage using the overall neuropathiescor (TNS)

most important knowledge

neurotoxicity occurred in the vitamin E group compared to 42 % in the placebo group ( p <0.01). The severe neurological damage in the vitamin E group was also significantly lower (1.4 TNS vs. 4.1; p <0.01).

effects on practice

The use of cisplatin is restricted by severe neurotoxicity. If the cumulative dose exceeds 300 mg/m2, it is reported to some patients considerable neurological damage. It is known that Cisplatin increases oxidative stress; Vitamin E is an antioxidant, and current findings indicate that the antioxidant effects of vitamin E do not affect the therapeutic effect of chemotherapy. 1 It has been reported that neuropathy occurs in the context of a vitamin E lack. Therefore, researchers are interested in examining the ability of vitamin E to protect against cisplatin-induced neuropathies.

researchers are interested in researching the ability of vitamin E, protecting against cisplatin-induced neuropathies.

In 2007, a Cochrane review concluded that earlier evidence that was used to protect vitamin E with the protection against neuropathy in patients who cisplatin were administered were encouraging, but would be able to support additional support from randomized clinical studies. Until there are further knowledge, all patients who are given cisplatin should take vitamin E preparations several days before the start of chemotherapy.